In Vitro Activity of the Novel Antifungal Olorofim against Scedosporium and Lomentospora prolificans.
Microbiol Spectr
; 11(1): e0278922, 2023 02 14.
Article
em En
| MEDLINE
| ID: mdl-36629417
ABSTRACT
Scedosporium spp. and Lomentospora prolificans are an emerging group of fungi refractory to current antifungal treatments. These species largely affect immunocompromised individuals but can also be lung colonizers in cystic fibrosis patients. Although Scedosporium apiospermum is thought to be the predominant species, the group has been expanded to a species complex. The distribution of species within the S. apiospermum species complex and other closely related species in the United States is largely unknown. Here, we used ß-tubulin and ITS sequences to identify 37 Scedosporium isolates to the species level. These Scedosporium isolates as well as 13 L. prolificans isolates were tested against a panel of nine antifungal drugs, including the first in novel class orotimide, olorofim. IMPORTANCE Scedosporium and Lomentospora infections are notoriously hard to treat as these organisms can be resistant to numerous antifungals. The manuscript contributes to our knowledge of the activity of the new antifungal agent olorofim and comparator agents against Lomentospora and against Scedosporium isolates that have been molecularly identified to the species level. The efficacy of olorofim against all species of Scedosporium and Lomentospora was confirmed.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ascomicetos
/
Scedosporium
Limite:
Humans
Idioma:
En
Revista:
Microbiol Spectr
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos